NucleBio’s New Prostac Test May Improve Diagnosis of Aggressive Prostate Cancer, Company Says

NucleBio’s New Prostac Test May Improve Diagnosis of Aggressive Prostate Cancer, Company Says
A new test called Prostac is able to accurately tell the difference between benign and aggressive prostate cancer, which has the potential to significantly improve men's healthcare, according to developer NucleoBio. "Prostac is a non-invasive, urine-based test that will resolve numerous flaws in existing prostate cancer screening methods," Charles Oyesile, MD, PhD, NucleoBio’s CEO and co-founder, said in a press release. The
Subscribe or to access all post and page content.